

my Newborn

genetic screening test that analyzes actionable genetic diseases of childhood onset

Veritas
a LetsGetChecked company

veritasint.com

my Newborn

Up to 9.4%[1] of newborns can present genetic variants related to childhood-onset diseases

Knowing this risk is key to intervene and personalize the newborn's management

What is myNewborn?

The test allows knowing the newborn risk to develop around **390 diseases with onset in the first years of life.** The test complements the heel prick test, improving the clinical utility.

What does the test include?

The test analyzes more than **400 genes through Whole Exome Sequencing** (WES).

What type of diseases are included?

- Highly actionable childhood onset diseases.
- Included in the newborn heel prick test.
- Adult onset diseases that are actionable during childhood.
- Common although not treatable diseases, with carrier frequency higher than 1/100.

Why prescribe myNewborn?

myNewborn entails an expansion of the conventional neonatal biochemical screening test, increasing the metabolic and genetic diseases detected, which allows nutritional intervention and other procedures during the childhood, improving the newborn's health.

Who is it intended for?

myNewborn is for any newborn without disease symptoms.

Counseling service for the specialist

Veritas offers a distinguishing service providing counseling to the physician for patient results interpretation, if it is needed.

Which sample type is needed?

Blood or buccal swab in a specific kit provided by Veritas.



1. Ceyhan-Birsoy, Ozge, et al. "Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project." The American Journal of Human Genetics 104.1 (2019): 76-93.

myNewborn clinical application examples

PATHOLOGY/GENE	SYMPTOMATOLOGY	PATIENT MANAGEMENT	
Glucose-6-Phosphate Dehydrogenase Deficiency *(G6PD)*	*Hemolytic anemia when beans, sulfites, specific drugs or food colorings are consumed.*	Dietary modifications and avoid specific drugs	Child without symptomatology
Familial hypercholesterolemia (*LDLR*)	*Early cardiovascular (CV) disease.*	Dietary modification + medication	Prevention of CV disease
Abetalipoproteinemia (*MTTP*)	*Fat absorption inability that alters the nervous system development.*	Low-fat diet + vitamin supplements	Prevention of neuropathy and ataxia

Types of diseases included in myNewborn

Percentage of diseases included in **myNewborn** by category



Classification of the **myNewborn** pathologies by clinical management



Metabolic
Syndromic
Pulmonary
Musculoskeletal
Hematologic
Endocrine
Neurological
Cardiovascular
Deafness
Immunological
Cancer
Urogenital
Preventive management
Early management
Dietary management
Other type of intervention

Whole exome technical information

- Veritas whole exome sequencing has an optimized design that improves the coverage for a more homogeneous sequencing of the exome.
- Whole exome sequencing with 100x average coverage, sequencing more than 99% of the genes of interest at ≥20x.
- Veritas has a team of expert curators who perform the interpretation based on the most up-to-date scientific knowledge, with a specialized software developed for a detailed variant classification.

Newborn Screening Procedure



References

» Zook JM. et al. Extensive sequencing of seven human genomes to characterize benchmark reference materials. Sci Data 2016;3:160025 doi: 10.1038/sdata.2016.25. PMID: 27271295.

» Mandelker D et al. Navigating highly homologous genes in a molecular diagnostic setting: a resource for clinical next-generation sequencing. Genet Med 2016;18:1282-1289. PMID: 27228465.

» Landrum MJ et al. ClinVar: public archive of interpretations of clinically relevant variants. Nuc Acids Res.

» 2016;44(1):D862–D868. doi: 10.1093/nar/gkv1222. PMID 26582918.

» Richards S et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med 2015;17:405-424. PMID 25741868.

» Stenson PD et al. The Human Gene Mutation Database: towards a comprehensive repository of inherited mutation data for medical research, genetic diagnosis and next-generation sequencing studies. Hum Genet 2017;136:665-677. PMID:28349240.

» Ceyhan-Birsoy, Ozge, et al. "Interpretation of Genomic Sequencing Results in Healthy and Ill Newborns: Results from the BabySeq Project." The American Journal of Human Genetics 104.1 (2019): 76-93.

» Holm, Ingrid A., et al. "The BabySeq project: implementing genomic sequencing in newborns." BMC pediatrics 18.1 (2018): 225.

Veritas was founded in 2018 by Dr. Luis Izquierdo, Dr. Vincenzo Cirigliano and Javier de Echevarría, who accumulate extensive experience in the field of genetics, diagnostics and biotechnology. Initially linked to Veritas Genetics, a company founded in 2014 by Prof. George Church, one of the pioneers in preventive medicine, Veritas was born with the aim of making genome sequencing and its clinical interpretation available to all citizens as a tool to prevent diseases and improve health and quality of life.

Since its inception, Veritas has led the activity and development in the markets in which it operates, with the goal of turning genomics into a daily instrument at the service of people's well-being.

In March 2022 Veritas announces that it will become part of LetsGet-Checked, a global healthcare solutions company based in Dublin and New York.

Veritas

a LetsGetChecked company

info@veritasint.com

veritasint.com

MB_MN_EN_V2.0
03/11/2022